George Robert Painter III, PhD

Title: Director
Company: The Emory Institute for Drug Development
Location: Atlanta, Georgia, United States

George Robert Painter III, PhD, Director at the Emory Institute for Drug Development, has been recognized by Marquis Who’s Who Top Scientists for dedication, achievements, and leadership in pharmacology and virology.

Discovering his love for the sciences at a young age, Dr. Painter soon realized that the specialty of virology would offer him the opportunity to conduct research in the sciences, as well as travel across the globe to help others. Attending Emory University, he received a Bachelor of Science in chemistry, a Master of Science in physical organic chemistry and a Doctor of Philosophy in synthetic chemistry, which he attained in 1977. At the inception of his career, he served Glaxo, Inc. as director of research process and international deputy therapeutic head of antiviral research before serving Burroughs Co. as the director of chemistry and director of virology, roles he maintained for 14 years. For the following six years, he served as the co-founder and executive vice president of research and development for Triangle Pharmaceuticals.

From 2002 to 2010, Dr. Painter excelled as the founder and chief executive officer of Connerix. Since 2010, he has flourished as the director of the Emory Institute for Drug Development, where he has also served as a professor of pharmacology and chemical biology. Throughout his career, he has directed the establishment of a freestanding drug discovery and development company within the university structure, and he has been a co-inventor of more than 45 patents. Notably, six of his patents have led to approved, commercially-available drugs or the combination of drugs for the treatment of such viral infections as HIV and hepatitis B. He is credited with the development of Emtricitabine in 2016, a drug used to treat HIV/AIDS.

Dr. Painter has maintained affiliation with the American Chemical Society, the American Society of Microbiology and the International Society for Antiviral Research. He attributes his success to hard work and his passion for the field. Although his career has been filled with highlights, he is especially proud of developing antiviral agents to treat HIV infections. Looking forward, he intends to continue experiencing the growth and success of his career, as well as pursue further medical research to help the needs of underserved populations.

Contact Dr. Painter:

Leave a Reply